Evidence map›Paper›PMID 37074431›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Drivers of Decline in Diarrhea Mortality Between GEMS and VIDA Studies.

Emily L Deichsel, Helen Powell, Christopher Troeger, M Jahangir Hossain, Samba O Sow, Richard Omore, Momodou Jasseh, Uma Onwuchekwa, David Obor, Doh Sanogo and 4 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Emily L DeichselCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Helen PowellCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Christopher TroegerInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.
M Jahangir HossainMedical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia.
Samba O SowCentre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.
Richard OmoreKenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.
Momodou JassehMedical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia.
Uma OnwuchekwaCentre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.
David OborKenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.
Doh SanogoCentre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.
Joquina Chiquita M JonesMedical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia.
Dilruba NasrinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Milagritos D TapiaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Karen L KotloffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
University of Maryland, Baltimore · USCentre Pour le Développement des Vaccins-Mali · MLMRC Unit the Gambia · GMKenya Medical Research Institute · KEInstitute for Health Metrics and Evaluation · US

Funding

FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
NIAID NIH HHS T32 AI007524
6 · The paper itself

Abstract

backgroundStatistical modeling suggests that decreasing diarrhea-associated mortality rates in recent decades are largely attributed to improved case management, rotavirus vaccine, and economic development.

methodsWe examined data collected in 2 multisite population-based diarrhea case-control studies, both conducted in The Gambia, Kenya, and Mali: the Global Enteric Multicenter Study (GEMS; 2008-2011) and Vaccine Impact on Diarrhea in Africa (VIDA; 2015-2018). Population-level diarrhea mortality and risk factor prevalence, estimated using these study data, were used to calculate the attribution of risk factors and interventions for diarrhea mortality using a counterfactual framework. We performed a decomposition of the effects of the changes in exposure to each risk factor between GEMS and VIDA on diarrhea mortality for each site.

resultsDiarrhea mortality among children under 5 in our African sites decreased by 65.3% (95% confidence interval [CI]: -80.0%, -45.0%) from GEMS to VIDA. Kenya and Mali had large relative declines in diarrhea mortality between the 2 periods with 85.9% (95% CI: -95.1%, -71.5%) and 78.0% (95% CI: -96.0%, 36.3%) reductions, respectively. Among the risk factors considered, the largest declines in diarrhea mortality between the 2 study periods were attributed to reduction in childhood wasting (27.2%; 95% CI: -39.3%, -16.8%) and an increased rotavirus vaccine coverage (23.1%; 95% CI: -28.4%, -19.4%), zinc for diarrhea treatment (12.1%; 95% CI: -16.0%, -8.9%), and oral rehydration salts (ORS) for diarrhea treatment (10.2%).

conclusionsThe VIDA study sites demonstrated exceptional reduction in diarrhea mortality over the last decade. Site-specific differences highlight an opportunity for implementation science in collaboration with policymakers to improve the equitable coverage of these interventions globally.

Indexed as

Rotavirus InfectionsRotavirus VaccinesChildDiarrheaHumansInfantKenyaModels, StatisticalRisk FactorsRotavirus VaccinesGEMSrotavirus vaccineVIDA

Identifiers

PMID37074431
PMCPMC10116520
OpenAlexW4366352624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.